Navigation Links
Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies
Date:10/20/2008

EXTON, Pa., Oct. 20 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE) announced today that the Company will host an investor conference call and webcast on Wednesday, October 22 at 4:30 PM Eastern Time to present an analysis of the data from the Isolagen Therapy(TM) Phase III pivotal studies (IT-R-005 and IT-R-006) for the treatment of nasolabial folds, or wrinkles. On August 5, 2008, Isolagen reported positive top-line efficacy and safety results from these two studies, which met all primary endpoints and were highly statistically significant.

The call participants will include Declan Daly, Isolagen's CEO, Dr. Stacy Smith, the Principal Investigator in the Phase III wrinkle studies and Co-Principal Investigator in the Phase II/III acne study, and Dr. Jeanne Novak, Clinical and Regulatory advisor to Isolagen.

A live webcast of the presentation will be accessible on http://www.isolagen.com. To participate in the audio portion of the call, dial 1-800-299-0433 and enter passcode 78803320. An archived replay of the conference call and webcast will be available for 90 days on http://www.isolagen.com or by dialing 1-888-286-8010 and entering passcode 63040312.

About Isolagen, Inc.

Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit http://www.isolagen.com.

Isolagen Forward Looking Statements

All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as updated in Item 1A. "Risk Factors" in the Company's Quarterly Reports on Form 10-Q. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as well as other public filings with the SEC since such date.


'/>"/>
SOURCE Isolagen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Isolagen to Present at the JMP Securities Healthcare Focus Conference
2. Isolagen to Present at the Morgan Stanley Global Healthcare Unplugged Conference
3. Isolagen, Inc. Reports Results of Shareholders Annual Meeting
4. Pharmaxis Investor Conference Call
5. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
6. The Michigan Life Sciences Pipeline Announces The Funding Place(TM) and Other Resources to Connect Investors and Startups
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference
8. Halozyme Therapeutics to Host Research Day for Investors and Analysts
9. Cell Therapeutics Provides Details on Investor & Media Day to be Held in Milan, Italy on Friday, October 3, 2008
10. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
11. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):